Enhertu-Induced Resistant Tumor Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused on ADC therapeutics against breast and lung cancer.

Learn about our comprehensive platform of ADC services by clicking HERE

Enhertu-induced resistant tumor models


← Return to Resources
× peptide, amino acid

Contact An Expert Today!